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Abstract
GIP action in type 2 diabetic (T2D) patients is altered. We hypothesized that methylation changes could be present in GIP
receptor of T2D patients. This study aimed to assess the differences in DNA methylation profile of GIPR promoter between
T2D patients and age- and Body Mass Index (BMI)-matched controls. We included 93 T2D patients (cases) that were uniquely
on diet (without any anti-diabetic pharmacological treatment). We matched one control (with oral glucose tolerance test
negative, non diabetic), by age and BMI, for every case. Cytokines and hormones were determined by ELISA. DNA was
extracted from whole blood and DNA methylation was assessed using the Sequenom EpiTYPER system. Our results showed
that T2D patients were more insulin resistant and had a poorer b cell function than their controls. Fasting adiponectin was
lower in T2D patients as compared to controls (7.063.8 mgr/mL vs. 10.064.2 mgr/mL). Levels of IL 12 in serum were almost
double in T2D patients (52.8658.3 pg/mL vs. 29.7637.4 pg/mL). We found that GIPR promoter was hypomethylated in T2D
patients as compared to controls. In addition, HOMA-IR and fasting glucose correlated negatively with mean methylation of
GIPR promoter, especially in T2D patients. This case-control study confirms that newly diagnosed, drug-naı̈ve T2D patients
are more insulin resistant and have worse b cell function than age- and BMI-matched controls, which is partly related to
changes in the insulin-sensitizing metabolites (adiponectin), in the proinflammatory profile (IL12) and we suggest in the
methylation pattern of GIPR. Our study provides novel findings on GIPR promoter methylation profile which may improve
our ability to understand type 2 diabetes pathogenesis.
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Introduction
Twin cohort studies have shown that shared genetic factors can
only explain a fraction of the differences in incident type 2 diabetes
(T2D) [1]. Behavioral (sedentary lifestyle, westernized food
patterns) and environmental factors (organic pesticides, chemical
exposures, and air pollutants) contribute to the development of
T2D [2]. Moreover, inflammation induces inhibition of the insulin
signalling pathway which can lead to insulin resistance and T2D.
Recently, it has been proposed that epigenetic mechanisms could
be involved in the complex interplay between genes and the
environment [3]. Indeed, a recent study showed the presence of an
epigenetic dysregulation in pancreatic islets from T2D patients [4].
Briefly, they found differences in DNA methylation profiles in
several promoter regions in islets from T2D patients [4]. DNA
methylation is the best studied epigenetic modification and
influences transcripcional regulation [5]. DNA methylation is a
reversible process that can be modulated by both stochastic and
environmental stimuli [6]. On the other hand, GIPR gene codifies
for the receptor of the incretin GIP, a gastrointestinal hormone
that stimulates insulin response after an oral glucose challenge. In
T2D patients, GIP action is reduced, whereas its secretion does
not seem to be altered. There is increasing evidence supporting an
important role for GIPR as a candidate for mediating insulin
secretion after oral glucose challenge [7]. We speculated that GIPR
gene could be affected by alterations in DNA methylation in T2D
patients, which could explain the dysregulation of GIP action in
T2D patients [8,9]. As DNA methylation occurs principally in the
upstream regulatory regions of the genes [10], we concentrated on
the promoter of GIPR. A previous study has shown that T2D-
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related methylation may be reflected in accessible tissues such as
peripheral blood [11].
The principal aim of this study was to compare the pattern of
DNA methylation on GIPR promoter between T2D patients and
age- and Body Mass Index (BMI)-matched controls. The
secondary aims were to compare the metabolic and cytokine
profiles between T2D patients and matched controls.
Materials and Methods
Ethics Statement
This study was approved by the ethics committees of the
Hospital Clı́nic and complies with all laws and international ethics
guidelines outlined in the Declaration of Helsinki. All human
subjects provided written, informed consent.
Study Design and Subjects Included
We conducted a case-control study where cases were defined as
patients suffering from T2D that were treated only by diet.
Eligibility criteria for cases were the following: clinical diagnosis of
T2D between December 2010 until December 2011, adequate
glycemic control after a period of minimum six months of low-
carbohydrate diet and lifestyle interventions, no pharmacological
therapy for T2D needed to achieve the glycemic control.
Diagnosis of T2D was done following ADA recommendations
[12], by either a random elevated fasting glucose value (confirmed
twice) and/or by performing an oral glucose tolerance test
(OGTT). In case oral medication was needed for optimal glycemic
control, those patients were excluded from the study. Cases and
controls were recruited from the same primary health center.
Eligibility criteria for controls were as follows: a negative OGTT at
recruitment, no previous diagnosis of T2D or prediabetes, no
chronic treatment with oral steroids. Controls were frequency
matched on age and BMI to cases. Metabolic profile, cytokine
profile and DNA methylation of GIPR promoter profile in
peripheral blood DNA were studied for all subjects (93 cases
and 93 controls).
Metabolic Assessments
All subjects were examined by anthropometric measurements
and had fasting metabolic assessments at recruitment. These
assessments included fasting glucose, fasting insulin, fasting leptin,
fasting adiponectin, cytokines, glycohemoglobin A1 (HbA1) (only
for the type 2 diabetic patients), HOMA-IR and HOMA-B.
HOMA-IR was calculated as follows: HOMA-IR= (FPI6FPG)/
22.5 [13]; homeostasis b-cell function (HOMA-B) = (20 6 FPI)/
(FPG 2 3.5), where FPI is the fasting plasma insulin concentration
(mU/l) and FPG is fasting plasma glucose (mmol/l) [14].
Hormone and Cytokine Measurements
Adiponectin, leptin and insulin were quantified from serum
samples by ELISA (Mercodia), according to the manufacturer’s
instructions. Cytokines were measured from serum samples using
CBA Human Inflammatory Cytokines kit (BD Bioscience),
following the manufacturers instructions. Two-color flow cyto-
metric analysis was performed using LSRFortessa (BD bioscience).
Data were acquired and analyzed using FACS Diva and FCAP
Array 1.01 Software. Hormone and cytokine measurements were
performed at the Diabetes and Obesity Laboratory-IDIBAPS;
Barcelona, Spain.
DNA Methylation Analysis
Whole blood samples were stored in the Biobank Hospital
Clı́nic-IDIBAPS; Barcelona, Spain. Genomic DNA was extracted
from whole blood for all the subjects studied using standards
procedures from the Biobank. Sequenom’s MassARRAY platform
was used to perform quantitative methylation analysis [15]. This
system utilizes MALDI-TOF mass spectrometry in combination
with RNA base-specific cleavage (MassCLEAVE). A detectable
pattern is then analyzed for methylation status. PCR primers for
the amplification of the GIPR promoter gene were designed using
Epidesigner (See Appendix S1).
Statistical Analysis
Descriptive data are presented as the mean and standard
deviation (SD) for continuous outcomes, or number and
percentage (%) for categorical outcomes. The methylation
values (in %), cytokines, HOMA-IR, HOMA-B, insulin, leptin
and adiponectin were compared using non-parametric Mann-
Whitney U test, because normality and equality of variance
could not be assumed. Student’s t test was used for the
comparison of the rest of continuous outcomes and Chi-square
test for categorical outcomes. Correlation between methylation
at all thirteen CpG sites was high (P=0.002), therefore a mean
of GIPR promoter methylation was generated. Spearman’s rank
correlation coefficient was used to assess correlation between
mean GIPR promoter methylation and the different covariates
(waist circumference, fasting glucose, fasting insulin, fasting
adiponectin, fasting leptin, HOMA-IR, HOMA-B, cytokines).
Linear regression was used to study the association between the
mean GIPR promoter methylation (independent variable) and
the covariates (dependent variables) that presented a significant
correlation in the Spearman analysis, after adjustment for
diabetis status (i.e, being case or control), sex, age and BMI.
Mean GIPR promoter methylation was log-transformed for the
regression analysis. Subgroup analyses (i.e, by disease status)
were done for the variables that remained significant after the
adjustment. Overall R2 values for the models give the combined
contribution of log-transformed mean GIPR promoter methyl-
ation, sex, age, BMI and diabetes status to the variability in
dependent variables. Bonferroni correction was used for multiple
comparisons. All significance tests were 2-tailed and values of
p,0.05 were considered significant. All analyses were conducted
using the statistical software package Stata version 11.
Results
Metabolic and Cytokine Profile of Type 2 Diabetic
Patients and Controls
Baseline characteristics of the patients included in the study
are summarized in Table 1. T2D patients had a higher waist
circumference as compared to controls (mean waist values of
102.769.5 cm vs. 97.968.0 cm, P,0.01). Fasting adiponectin
was lower in cases as compared to controls (mean values of
7.063.8 mgr/mL vs. 10.064.2 mgr/mL, P,0.0001). HOMA-IR
was higher in cases (2.661.5 vs. 1.860.7 in controls,
P,0.0001). HOMA-B was higher in controls as compared to
T2D patients (113.66510.6 vs. 75.7651.1 in type 2 diabetic
patients, P,0.0001). From the cytokines analyzed, significant
differences were found for IL 10 (4.163.0 pg/mL in cases vs.
5.263.7 pg/mL in controls, P,0.05) and IL 12 (52.8658.3 pg/
mL in cases vs. 29.7637.4 pg/mL in controls, P,0.0001). No
differences were found between cases and controls in the routine
laboratory measures (blood cell count, hepatic profile, lipid
profile, renal function, data not shown).
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Quantitative DNA Methylation Analysis in Peripheral
Blood of GIPR Promoter in Type 2 Diabetic Patients and
Controls
Methylation levels in DNA from whole blood of 186 subjects
were obtained for 13 CpG sites covering 1,000 bp upstream of the
first exon of the human GIPR gene. The heatmap showing the
values of methylation (%) for each CpG site analyzed did not
reveal a clearly distinct pattern of methylation between T2D
patients and controls (figure not shown); however some significant
differences were found. Indeed, 9 out of 13 CpG sites studied
(69%) showed significant differences between T2D patients and
controls. There was a trend towards an hypomethylation in T2D
patients as compared to controls (See Table S1). In fact, mean
GIPR promoter methylation was lower in T2D patients as
compared to controls (24.361.6 in cases vs. 26.261.5 in controls,
P,0.0001). Mean methylation of GIPR promoter was correlated
with waist circumference (r =20.26, P,0.01), fasting glucose
(r =20.50, P,0.0001), HOMA-IR (r =20.29, P,0.001),
HOMA-B (r = 0.28, P,0.001), fasting adiponectin (r = 0.23,
P,0.01) and IL-12 (r =20.22, P,0.01) (see Table 2). After
adjustment, increased GIPR promoter methylation was associated
with decreasing fasting glucose [22.4 (24.5 to 20.2), P,0.05]
and decreasing HOMA-IR [24.6 (27.5 to 21.8) P,0.01] (see
Figure 1). Hence, following a 10% increase in log-transformed
GIPR promoter methylation, fasting glucose and HOMA-IR
decrease by 0.24 mmol/L and 0.46 units, respectively (see
Table 2). The combined contribution of GIPR promoter methyl-
ation and diabetes status, age, sex and BMI to the variability in
HOMA-IR was up to 23% and up to 53% regarding fasting
glucose (see Table 2). Separate analyses of T2D patients and
controls showed that the significant inverse correlation between
mean GIPR methylation and HOMA-IR was mostly present in
T2D patients (P,0.05) and not in controls (P=0.06) (see Figure 2).
Regarding fasting glucose, the relationship remained significant
also uniquely for T2D patients (P,0.05), and not in controls
(P=0.80).
Discussion
The leading cause of T2D is thought to be an impaired b cell
function [16] which depends on a complex interplay of genetic
predisposition and environmental factors, such as obesity, inactiv-
ity and aging. In this sense, we aimed to compare, given a similar
environment (defined as similar age and similar degree of obesity),
which were the factors associated with the apparition of T2D.
Therefore, we compared the metabolic and cytokine profile
between 93 newly diagnosed T2D patients and 93 age- and BMI-
matched controls. In addition, we also performed the first DNA
methylation profiling of human peripheral blood covering the
promoter of glucose-associated gene GIPR in T2D patients and
controls.
T2D patients and controls were similar in age and BMI to
control for any confounder effect of age and obesity on the results.
Moreover, none of the T2D patients were on any pharmacological
therapy for diabetes. Thus, no confounding effect of antidiabetic
drugs or insulin therapy was possible, either. T2D patients had
their clinical diagnosis of T2D recently and were in optimal
glycemic control. Hence, no potential influence of hyperglycemia
on the methylation pattern was possibe, or, if any, was low. Results
showed that T2D patients were more insulin-resistant than
controls, since they presented higher values of HOMA-IR. In
concordance to this, T2D patients had a higher waist circumfer-
ence as compared to controls. Large waist circumference is one
component used for the diagnosis of the metabolic syndrome.
Insulin resistance is associated with metabolic syndrome too [17].
Basically, in spite of the fact that T2D patients and controls had a
similar grade of obesity, T2D patients presented a differential body
fat distribution (particularly centralized obesity). This correlates
with a differential adipokines secretion which might lead to a
higher degree of insulin resistance in T2D patients. In contrast,
and as expected, b cell function was already impaired in T2D
patients as compared to controls (HOMA-B was significantly
lower in T2D patients as compared to controls). These data
illustrates the fact that impairment of b cell function is worse in
Table 1. Demographic and metabolic characteristics of type 2 diabetic patients and age- and BMI-matched controls.
Variable*
Type 2 diabetic patients
(n =93) Controls (n =93) P Value{
Demographic characteristics
Age, yr 69.169.2 66.6611.7 Matching variable
BMI, kg/m2 29.263.7 28.862.5 Matching variable
Waist circumference, cm 102.769.5 97.968.0 ,0.01
Male sex, (%) 66.7 53.8 0.07
Laboratory values
Fasting glucose, (mmol/L) 6.461.2 4.660.4 ,0.0001
Glycated hemoglobin, (%) 5?860.6 –
Fasting insulin, (pmol/L) 55.6628.6 52.4621.1 0.39
HOMA-IR ` 2.661.5 1.860.7 ,0.0001
HOMA-B 1 75.7651.1 113.66510.6 ,0.0001
Fasting leptin, (ng/mL) 18.0616.7 25.4626.8 0.07
Fasting adiponectin, (mg/mL) 7.063.8 10.064.2 ,0.0001
*Values shown are means 6SD, unless otherwise indicated.
{P values were calculated with the t test for quantitative variables or Chi-square test for categorical ones, except for HOMA-IR, HOMA-B, fasting insulin, fasting leptin and
fasting adiponectin, where non-parametric Mann-Whitney U test was applied.
`HOMA-IR was calculated as [Insulin mUI/l x Glycemia: (mmol/l)/22.5].
1HOMA-B was calculated as (20 6 FPI)/(FPG 2 3.5), where FPI is the fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/l).
doi:10.1371/journal.pone.0075474.t001
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T2D patients compared to age- and BMI- matched controls.
These results are in concordance with the existing literature [18].
In addition, we found that T2D patients had lower adiponectin
levels in serum than controls. Epidemiological studies have shown
that higher adiponectin levels in serum are associated with a lower
risk of T2D_ENREF_19. Moreover, adiponectin has been
proposed as a strong biochemical predictor of T2D [19].
Adiponectin is exclusively and abundantly expressed in white
adipose tissue and has been shown to have insulin-sensitizing and
anti-inflammatory properties [20]. In fact, in our study, we found
that fasting adiponectin had a negative correlation with HOMA-
IR (Spearman correlation coefficient r =20.28, P,0.0001) and a
positive correlation with HOMA-B (r = 0.19, P,0.01), which
supports the insulin-sensitizing properties of adiponectin.
Figure 1. Correlation between average GIPR promoter methylation from peripheral blood DNA and insulin resistance. Log-
transformed average GIPR promoter methylation is shown as the independent variable. HOMA-IR was used as a marker of insulin resistance.
Spearman ‘s correlation r =20.29, P= 0.0001. Adjusted P,0.01 (diabetes status, age, BMI and gender).
doi:10.1371/journal.pone.0075474.g001
Figure 2. Correlation between average GIPR promoter methylation from peripheral blood DNA and insulin resistance, by
subgroups (Type 2 diabetic patients and controls). Log-transformed average GIPR promoter methylation is shown as the independent
variable. HOMA-IR was used as a marker of insulin resistance. P= 0.06, adjusted for age, BMI and gender in controls (n = 93). P,0.05, adjusted for age,
BMI and gender in patients with Type 2 diabetes (n = 93).
doi:10.1371/journal.pone.0075474.g002
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On the other hand, lower levels of the anti-inflammatory IL-10
were found in T2D patients, which is consistent with previous
research that showed that low levels of IL 10 are associated with
T2D [21]. IL-12 serum levels were almost double in T2D patients
than in controls. A recent study showed that elevated serum IL-12
was present at the onset of T2D, and that further increases in IL-
12 correlated with endothelial dysfunction and cardiovascular
disease progression [22]. In addition, it has also been showed that
IL-12 might have a role in b cell dysfunction [23]. Overall, the first
part of our research demonstrate that T2D patients have an
impaired b cell function and are more insulin resistant than age-
and BMI-matched controls. These differences in b cell function
and insulin resistance are related to differences in adipokines and
inflammatory metabolites, which might be the underlying
mechanisms that lead to overt T2D [24].
Next, we performed a DNA methylation profiling of GIPR
promoter in DNA from peripheral blood and we sought for
associations of methylation with blood-and T2D-based biomark-
ers. We found that GIPR promoter was hypomethylated in T2D
patients as compared to controls. These results are consistent with
a recent study which showed that hypomethylation in specific
genomic regions in peripheral blood DNA was associated with
T2D [11]. However, their analysis did not cover the genomic
region we studied. To our knowledge, GIPR promoter methylation
analysis in peripheral blood DNA between T2D patients and age-
and BMI-matched controls has not been done before. There is
great interest to perform methylation profiling in peripheral blood
to find methylation disease-related associations since specific
methylated regions could be used as potent biomarkers [25].
However, to understand how these methylated regions have a
mechanistic role in the development of the disease of interest, the
methylation analysis should focus in the target-tissues of the genes
studied. GIPR, or gastric inhibitory polypeptide receptor, gene is
expressed in various tissues, including b cells, adipose tissue, and
brain [26]. It has been shown that GIPR expression is down-
regulated in pancreatic tissue of T2D patients [27]. Here, we
found that methylation of GIPR promoter in blood was negatively
correlated with a surrogate marker of insulin resistance (HOMA-
IR) and fasting glucose. In other words, decreased methylation in
this promoter is associated with higher insulin resistance and
higher fasting glucose. The subgroup analysis showed that this
association was mostly relevant for T2D patients. The mechanisms
underlying this association remain unknown and were not the
purpose of the current research. On the other hand, methylation
of GIPR promoter was not associated with HOMA-B. It has been
shown that GIPR is involved in obesity and insulin resistance [28].
Recently, GIP was proposed as having a role in inflammation and
insulin resistance by modulating the expression of osteopontin in
adipose tissue [29]. Moreover, carriers of GIPR rs10423928 A-
allele showed better insulin sensitivity [29]. The possible DNA
methylation contribution to these effects has not been studied yet
and warrants further study. Methylation patterns are thought to be
tissue-specific [4,5], thus we might not extrapolate the methylation
pattern found in blood to the methylation pattern present in
adipose tissue. Further research is needed to define the role of
methylation changes in GIPR promoter in adipose tissue and their
potential impact on insulin resistance.
The strength of our research is that we have demonstrated that
newly diagnosed and drug-naı̈ve T2D patients have differences in
specific hormones (adiponectin) and proinflammatory metabolites
(especially IL 12) as compared to age- and BMI-matched controls.
We also found that GIPR promoter was hypomethylated in T2D
patients as compared to controls, as well as, new correlations
between insulin resistance, fasting glucose and GIPR promoter
methylation in DNA from peripheral blood. However, despite
accounting for the major confounding factors (age, BMI, diabetes
pharmacologic therapy), residual confounding and reverse causa-
tion remain possible. We cannot exclude a potential effect of the
diet on methylation results in cases. However, there is not
published data supporting that a low-carbohydrate diet would
affect the methylation pattern of GIPR promoter in peripheral
blood. We have already controlled for the potential effects of
hyperglycemia and antidiabetic medication on the methylation
values. A method for overcoming this issue, as proposed by Relton
et al [30], is by applying a ‘‘genetical epigenomics’’ approach. In our
case, this would mean to study the genetic variants that would be
related to the methylation pattern, and then to verify whether the
Table 2. Results of correlation analysis between GIPR promoter methylation and the listed dependent variables.
Outcome variable Spearman’s correlation Unadjusted p-value Adjusted p-value* R2 (%){
Waist circumference 20.26 ,0.01 0.59. b=25.2 (224.4 to 13.9) 44.8
Fasting glucose 20.50 ,0.0001 ,0.05. b=22.4 (24.5 to 20.2) 52.9
Fasting insulin 20.12 0.10
HOMA-IR 20.29 ,0.001 ,0.01. b=24.6 (27.5 to 21.8) 22.7
HOMA-B 0.28 ,0.001 0.53. b=20.5 (21.9 to 1.0) 39.4
Fasting leptin 20?05 0?49





IL-12 20.22 ,0.01 0.55. b=237.7 (2161.6 to 86.1) 6.1
TNFa 0.03 0.65
*Adjustment for age, BMI, sex and diabetes status by creating linear regression analyses between log-transformed GIPR promoter methylation and the dependent
variables that presented a significant correlation in Spearman’s analysis. Regression coefficients and corresponding 95% CIs are shown.
{R2 reflects the variance (%) in outcome measures accounted for age, BMI, sex, diabetes status and GIPR promoter methylation.
doi:10.1371/journal.pone.0075474.t002
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correlation with methylation values and insulin resistance remains.
However, this was out of scope of the present study.
In conclusion, our research showed that newly diagnosed and
drug-naı̈ve T2D patients have impaired b cell function and are
more insulin resistant as compared to age- and BMI-matched
controls. In addition, adiponectin was lower in T2D patients and
correlated with b cell function. IL-12 levels in serum were almost
double in T2D patients as compared to controls. The targeted
epigenetic analysis in DNA from peripheral blood identified that
GIPR promoter was hypomethylated in T2D patients as compared
to controls. Hypomethylation of GIPR promoter correlated with
higher fasting glucose and insulin resistance in T2D patients.
Further research should unveil the potential role of these findings
in the physiopathology of T2D.
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